Abstract
We have found the short-term MTT assay to be a simple, reproducible chemosensitivity technique, suitable for use throughout the time course of disease. We now have 12 years’ experience of using this method in a variety of tumour types, both haematological and solid malignancies. Tumour cells are isolated from bone marrow, malignant effusions or solid biopsies and subjected to drug exposure for 48–96 h. Cell survival is measured by re-incubation in MTT for 4 h. We have found a significant correlation of in vitro results with in vivo outcome for acute myeloid leukaemia (AML) and for ovarian cancer (both p<0.0001) with an assay sensitivity of 98% for AML and 81% for ovarian cancer. Furthermore, the 5-year survival of ovarian cancer patients treated with a drug found sensitive in vitro is significantly higher than that for patients treated with a drug found resistant in vitro (p=0.033). We have correlated assay results with drug resistance markers. For example, expression of the newly described half transporter BCRP is related to daunorubicin resistance (p<0.05). The MTT assay is also suitable for screening for modulation of drug resistance. We have found that the DNA polymerase inhibitor aphidicolin markedly increases in vitro sensitivity to the platinum drugs in ovarian cancer and cytosine arabinoside in AML in the majority of patients. The greatest effect was seen for patients deemed resistant in vitro to these agents. We have identified novel drug combinations which demonstrate significant synergism using this methodology and have also used it to study the emergence of drug resistance in cell line models with a view to its prevention. In conclusion, we have found the MTT assay to be a simple, repeatable, adaptable technique which produces accurate information to help the clinician select suitable treatment for individual cases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Black MM, Speer FD (1953) Effects of cancer chemotherapeutic agents on dehydrogenase activity of human cancer tissue in vitro. Am J Clin Pathol 23:218–227
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Methods 65:55–63
Carmichael J, De Graff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semi-automatic colorimetric assay. Cancer Res 47:936–942
Pieters R, Huismans DR, Leyva A, Veerman AJP (1988) Adaption of the rapid tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukaemia. Cancer Lett 41:323–332
Sargent JM, Taylor CG (1989) Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. Br J Cancer 60:206–210
Twentyman PR, Fox NE, Rees JKH (1989) Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay. Br J Haematol 71:19–24
Wilson JK, Sargent JM, Elgie AW, Hill JG, Taylor CG (1990) A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. Br J Cancer 62:189–194
Taylor CG, Sargent JM, Elgie AW, Reid FDA, Alton PA, Hill JG (1998) The clinical relevance of chemosensitivity testing in ovarian cancer. Cancer Detect Prev 22:305–312
Sargent J, Elgie A, Williamson C, Taylor C (1997) The use of the MTT assay to study drug resistance in acute myeloid leukaemia — an update. Adv Blood Dis 3:33–41
Taylor CG, Sargent JM, Elgie AW, Williamson CJ, Lewandowicz GM, Chappatte O, Hill JG (2001) Chemosensitivity testing predicts survival in ovarian cancer. Eur J Gynaecol Oncol 22:278–282
Gontero P, Sargent JM, Hopster DJ, Lewandowicz GM, Taylor CG, Elgie AW, Williamson CJ, Sriprasad SI, Muir GH In vitro chemosensitivity to mitomycin C in transitional cell carcinoma of the bladder and its relationship with P-glycoprotein and apoptotic factors. (submitted)
Sargent JM, Elgie AW, Williamson CJ, Lewandowicz GM, Taylor CG (2001) Circumvention of resistance to ara-C by aphidicolin in blast cells from patients with AML. Br J Cancer 84:680–685
Klumper E, Ossenkoppele GJ, Pieters R, Huismans DR, Loonen AH, Rottier A, Westra G, Veerman AJP (1996) In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br J Haematol 93:903–910
Elgie AW, Sargent JM, Williamson CJ, Lewandowicz GM, Taylor CG (1999) Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML. Adv Exp Med Biol 457:29–33
Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 22:15665–15670
Ross DD (2000) Novel mechanisms of drug resistance in leukemia. Leukemia 14:467–473
Scheffer GL, Maliepaard M, Pijnenborg ACLM, van Gastelen MA, de Jong MC, Schroeijers AB, van der Kolk DM, Allen JD, Ross DD, van der Valk P, Dalton WD, Schellens JHM, Scheper RJ (2000) Breast cancer resistance protein is localised at the plasma cell membrane in mitoxantrone-and topotecan-resistant cell lines. Cancer Res 60:2589–2593
Ross DD, Karp JE, Chen TT, Doyle LA (2000) Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96:365–368
Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, Taylor CG (2001) Breast cancer resistance protein and resistance to daunorubicin in blast cells from patients with AML. Br J Haematol 115:257–262
Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RCAM, de Jong LA, Pluim D, Beijnen JH, Schellens JHM (2001) Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 7:935–941
Covelli A (1999) Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol 10 (Supp 6):53–59
Kaye SB (1999) New drug development: its role in reversing drug resistance. Br J Cancer 80:116–121
Sargent J, Elgie A, Alton P, Taylor C (1995) Identification of drug resistance in fresh blast cells from acute myeloid leukaemia and its modification in vitro. Contrib Oncol 49:109–116
Sargent J, Elgie A, Taylor C, Wilson J, Alton P, Hill JG (1994) The identification of drug resistance in ovarian cancer and breast cancer: application of the MTT assay. Contrib Gynecol Obstet 19:64–75
Coley HC, Sargent JM, Williamson CJ, Titley J, Scheper R, Gregson SE, Elgie AW, Lewandowicz GM, Taylor CG (2002) Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility study. Anticancer Res 22:69–74
Lewandowicz GM, Britt P, Elgie AW, Williamson CJ, Coley HM, Hall AG, Sargent JM (2002) Cellular glutathione content and the effect of BSO modulation in tumour biopsies derived from patients with advanced ovarian cancer. Gynecol Oncol 85:298–304
Ikegami S, Taguchi T, Ohashi M, Oguro M, Nagano H, Mano Y (1978) Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-alpha. Nature 275:458–460
Yamade K, Itoh R (1994) Involvement of DNA polymerase d and/or e in joining UV-induced DNA single strand breaks in human fibroblasts (comparison of effects of butylphenyldeoxyguanosine with aphidicolin). Biochim Biophys Acta 1219:302–306
Sessa C, Zucchetti M, Davoli E, Califano R, Cavalli F, Fristaci S, Gumbrell L, Sulkes A, Winograd B, D'Incalci M (1991) Phase I and clinical evaluation of aphidicolin glycinate. J Natl Cancer Inst 83:1160–1164
Sargent JM, Elgie AW, Williamson CJ, Taylor CG (1996) Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours. Br J Cancer 74:1730–1733
Sargent JM, Taylor CG, Elgie AW (1993) Study of drug combinations in acute myeloid leukaemia (AML) using the MTT assay. In: Kaspers GJL et al (eds) Drug resistance in leukaemia and lymphoma — the clinical value of laboratory studies. Harwood Academic, London, pp 293–297
Taylor CG, Elgie AW, Williamson CJ, Sargent JM (2001) The combination of topotecan and daunorubicin shows striking synergism in vitro in AML. Leukemia 15:492 (abst O44)
Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15:1333–1340
Sargent JM, Williamson CJ, Taylor CG, Hellmann K (2001) Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562. Br J Cancer 84:959–964
Faulkner Pulsford J, Sargent J, Elgie A, Taylor C (1995) Comparison of P-glycoprotein expression with in vitro drug sensitivity in fresh blast cells from acute myeloid leukaemia. Br J Biomed Sci 52:188–194
Sargent JM, Coley HM, Williamson C, Taylor CG (1998) Evidence of ABC transporters in fresh tumor cells from patients with ovarian cancer. Int J Pharmacol Therapeut 36:64–66
Sargent JM, Williamson C, Hall AG, Elgie AW, Taylor CG (1999) Evidence for the involvement of the glutathione pathway in drug resistance in AML. Adv Expl Med Biol 457:205–209
Elgie AW, Sargent JM, Alton P, Peters GJ, Noordhuis P, Williamson CJ, Taylor CG (1998) Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML. Leuk Res 22:373–378
Balkham SE, Sargent JM, Elgie AW, Williamson CJ, Taylor CG (1999) Comparison of BCL-2 and BAX protein expression with in vitro sensitivity to ara-C and 6TG in AML Adv Expl Med Biol 457:335–340
Elgie AW, Sargent JM, Williamson CJ, Taylor CG (2001) Bcl-2, bax, hsp 70 expression and drug sensitivity in patients with AML. Leukemia 15:489 abst P17
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Sargent, J.M. (2003). The Use of the MTT Assay to Study Drug Resistance in Fresh Tumour Samples. In: Reinhold, U., Tilgen, W. (eds) Chemosensitivity Testing in Oncology. Recent Results in Cancer Research, vol 161. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19022-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-19022-3_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62412-4
Online ISBN: 978-3-642-19022-3
eBook Packages: Springer Book Archive